Chemotherapy Regimens Received by Women With BRCA1/2 Pathogenic Variants for Early Stage Breast Cancer Treatment | Zendy

Allison W. Kurian | Zendy; Paul Abrahamse | Zendy; Ann S. Hamilton | Zendy; Jennifer L. CaswellJin | Zendy; Scarlett Lin Gomez | Zendy; Timothy J Hofer | Zendy; Kevin C. Ward | Zendy; Steven J. Katz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Chemotherapy Regimens Received by Women With BRCA1/2 Pathogenic Variants for Early Stage Breast Cancer Treatment

Author(s) -

Allison W. Kurian,

Paul Abrahamse,

Ann S. Hamilton,

Jennifer L. CaswellJin,

Scarlett Lin Gomez,

Timothy J Hofer,

Kevin C. Ward,

Steven J. Katz

Publication year - 2022

Publication title -

jnci cancer spectrum

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.345

H-Index - 10

ISSN - 2515-5091

DOI - 10.1093/jncics/pkac045

Subject(s) - medicine , stage (stratigraphy) , breast cancer , oncology , chemotherapy , cancer , gynecology , paleontology , biology

Genetic testing is widespread among breast cancer patients; however, no guideline recommends using germline genetic testing results to select a chemotherapy regimen. It is unknown whether breast cancer patients who carry pathogenic variants (PVs) in BRCA1 and/or 2 (BRCA1/2) or other cancer-associated genes receive different chemotherapy regimens than noncarriers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research